08 ноября 2017, 19:47

Alnylam's (ALNY) Q3 Earnings, Revenues Miss Estimates

Alnylam Pharmaceuticals (ALNY) incurred wider than expected loss and missed sales estimates in the third quarter of 2017.

02 ноября 2017, 16:34

Sanofi (SNY) Q3 Earnings In Line, Sales Lag, Diabetes Weak

Sanofi's (SNY) Q3 results were mixed as it reported in-line earnings and missed sales expectations. Meanwhile, the outlook for the Diabetes franchise remains weak.

Выбор редакции
27 октября 2017, 18:30

BioMarin (BMRN) Q3 Loss Narrows, Profit Guidance Raised

BioMarin (BMRN) reported a narrower-than-expected loss in the third quarter of 2017 but missed estimates for sales. The biotech also raised its previously issued adjusted net income guidance for 2017.

29 сентября 2017, 16:13

Keryx Focuses on Kidney Drug Auryxia Despite Generic Threat

Keryx (KERX) is working on expanding its only marketed product, Auryxia's label.

28 сентября 2017, 16:23

Sanofi Rides on Genzyme & Vaccines Unit, Diabetes Sales Weak

Sanofi's (SNY) Genzyme and Vaccines units are driving sales. Sales from the Diabetes franchise however continue to drop.

11 июля 2017, 23:19

Alnylam (ALNY) Stock Down Despite Positive Hemophilia Data

Alnylam Pharmaceuticals, Inc. (ALNY) and Sanofi's (SNY) specialty care global business unit, Genzyme, announced encouraging results from the ongoing phase II open-label extension (OLE) study.

08 июня 2017, 16:47

BioMarin (BMRN) Down 8% Since Earnings Report: Can It Rebound?

BioMarin (BMRN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Выбор редакции
08 июня 2017, 10:31

Why Is Alnylam (ALNY) Up 31.2% Since the Last Earnings Report?

Alnylam (ALNY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

30 мая 2017, 16:01

Sanofi (SNY) Stock Continues to Gain on Key Drug Approvals

After declining in 2016, share price of French pharma giant Sanofi (SNY) has picked up in 2017.

Выбор редакции
Выбор редакции
08 мая 2017, 20:59

Alnylam (ALNY) Q1 Loss Wider than Expected, Revenues Up Y/Y

Alnylam Pharmaceuticals, Inc. (ALNY) reported a loss of $1.25 per share in the first quarter of 2017, wider than the Zacks Consensus Estimate of a loss of $1.22 and the year-ago loss of $1.21.

05 мая 2017, 17:37

Keryx (KERX) Q1 Loss Wider than Expected, Revenues Beat

Keryx Biopharmaceuticals Inc. (KERX) reported first-quarter 2017 loss of 21 cents per share, narrower than the year-ago loss of 39 cents

05 мая 2017, 17:30

BioMarin (BMRN) Posts Earnings in Q1, Sales Top, Stock Up

BioMarin Pharmaceutical Inc. (BMRN) reported earnings of 3 cents per share in the first quarter of 2017.

28 апреля 2017, 16:19

Sanofi (SNY) Q1 Earnings Top, Sales Rise Y/Y, Shares Up

Sanofi (SNY) reported first-quarter 2017 earnings of 75 cents per American depositary share, which beat the Zacks Consensus Estimate of 73 cents by 2.7%.

29 марта 2017, 17:21

Regeneron & Sanofi's Atopic Dermatitis Drug Gets FDA Nod

Regeneron Pharmaceuticals, Inc. (REGN) and its partner Sanofi (SNY) announced that the FDA has approved the Dupixent (dupilumab) Injection, for the treatment of adults with moderate-to-severe atopic dermatitis (AD).

28 марта 2017, 14:10

Why Is BioMarin (BMRN) Down 2.2% Since the Last Earnings Report?

BioMarin (BMRN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Выбор редакции
23 марта 2017, 13:16

Alnylam (ALNY) Up 14.5% Since Earnings Report: Can It Continue?

Alnylam (ALNY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

17 марта 2017, 01:12

Keryx Focuses on Kidney Drug Aurexia Despite Generic Threat

We issued an updated research report on Keryx Biopharmaceuticals, Inc. (KERX) on Mar 15, 2017.

08 марта 2017, 17:45

Ionis Pharma Lipid Disorder Candidate Positive in Phase III

Akcea Therapeutics, an affiliate of Ionis Pharmaceuticals, Inc. (IONS), recently announced positive results from a pivotal phase III study evaluating its pipeline candidate volanesorsen for treatment of patients with familial chylomicronemia syndrome.